
ARDT Stock Forecast & Price Target
ARDT Analyst Ratings
Bulls say
Ardent Health Inc. demonstrated strong financial performance with an EBITDA of $143 million, reflecting a 46% year-over-year increase and an improved margin of 9.1%, up by 240 basis points. The company experienced a 2.9% growth in admissions, aligning with its full-year outlook, while professional fees rose significantly by 11% in the most recent quarter, indicating continued investment in critical services such as anesthesia and radiology. Furthermore, Ardent's strategic focus on outpatient services and the positive trends within the hospital sector suggest substantial growth potential, positioning the company to capitalize on its under-earning capacity.
Bears say
Ardent Health's stock outlook is negatively impacted by a lower-than-expected underlying EBITDA performance, which was bolstered by one-time gains from Kansas SDPs, overshadowing ongoing revenue challenges. The company’s transition to the Kodiak revenue cycle management platform has resulted in a significant $43 million revenue adjustment, contributing to a conservative outlook on accounts receivable collectability and diminished growth expectations. Additionally, revised EBITDA-NCI estimates reflect a downward adjustment to $542 million for 2025 and $536 million for 2026, representing a combined reduction of approximately 9% in 2025 guidance, underscoring concerns about minimal to negative EBITDA growth moving forward.
This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.
ARDT Analyst Forecast & Price Prediction
Start investing in ARDT
Order type
Buy in
Order amount
Est. shares
0 shares